Although several biomarkers show promise, PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.
Men who had PSA relapse after receiving post-radical surgery salvage radiation therapy had a median overall survival of nearly 14 years.
New study highlights the importance of digital rectal examinations in PCa patients with normal-range PSA at diagnosis.
Reduced likelihood of biochemical recurrence of prostate cancer also linked to concomitant hormonal therapy and positive surgical margins.
Transient rises in PSA after radiotherapy may be due to late damage to healthy prostatic tissue, evidence suggests.
Immediate ADT found to offer little or no survival advantage to prostate cancer who experience biochemical recurrence.
This parameter can identify prostate cancer patients for whom adjuvant radiation therapy after radical prostatectomy may be of no benefit.
PSA bounce was associated with significantly higher scores on the International Index of Erectile Function-15 questionnaire.
Men diagnosed with low-risk prostate cancer today have lower PSA levels and tumor volume than men 15 years ago.
The nadir should be below 0.01 ng/mL because even levels of 0.01 to 0.2 ng/mL predict an increased risk of adverse outcomes.
Higher circulating tumor cell counts are associated with an increased risk of death.
Trend follows the 2012 release of a U.S. Preventive Services Task Force recommendation against such testing.
Elevated urinary levels of the organic compound were found in men with prostate cancer than in those without it.
High PSA and short PSA double time are associated with a greater likelihood of a positive bone scan.
Additional predictors guide selection of patients for active surveillance programs.
New nomogram could help clinicians and patients make treatment decisions.